Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
April 4, 2023Drugs in ContextOpen Access

Silymarin treatment and reduction of liver enzyme levels in non-alcoholic fatty liver disease: a case report

View Full Paper
Ask AI
Bookmark
Share

Authors

TCTanyaporn Chantarojanasiri

Discussion

Loading...

Member takes

Overview

Case report reveals reduced liver enzyme activity following silymarin therapy in an overweight patient with non-alcoholic fatty liver disease, suggesting potential supportive hepatoprotective utility.

Key Points

  • To assess the therapeutic effect and safety profile of silymarin on elevated liver enzyme activity in an overweight patient diagnosed with non-alcoholic fatty liver disease.
  • Conducted a clinical case report following CARE guidelines on a 70-year-old overweight male (BMI 26.4 kg/m²) with hypertension and non-alcoholic fatty liver disease.
  • Administered silymarin at an oral dosage of 140 mg twice daily.
  • Silymarin treatment produced a marked decrease in circulating liver enzyme activity.
  • The therapeutic regimen maintained a good safety profile with no reported adverse tolerability issues.

Cite This Study

Tanyaporn Chantarojanasiri (2023) studied this question.

synapsesocial.com/papers/6a987bc6b15fa94b4a3df452https://doi.org/10.7573/dic.2023-1-4
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Efficacy of different interventions for nonalcoholic fatty liver disease: A meta-analysis of lifestyle modifications, silymarin, and medications.2025
  2. 2Effects of Silymarin Combined with Herbal Medicine on Th17/Treg Cell Imbalance and Inflammatory Response in Patients with Nonalcoholic Fatty Liver Disease: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial2025 · 1 citations
  3. 3Silymarin-choline combination versus ursodeoxycholic acid in non-alcoholic fatty liver disease: A randomized double-blind clinical trial2024 · 1 citations
  4. 4Silymarin decreases liver stiffness associated with gut microbiota in patients with metabolic dysfunction-associated steatotic liver disease: a randomized, double-blind, placebo-controlled trial2024 · 30 citations
  5. 5Effects of Oral Administration of Silymarin in a Juvenile Murine Model of Non-alcoholic Steatohepatitis2017 · 42 citations